CRNX
Price
$29.96
Change
-$0.03 (-0.10%)
Updated
Jun 27 closing price
Capitalization
2.81B
41 days until earnings call
QURE
Price
$13.86
Change
-$0.37 (-2.60%)
Updated
Jun 27 closing price
Capitalization
759.91M
33 days until earnings call
Interact to see
Advertisement

CRNX vs QURE

Header iconCRNX vs QURE Comparison
Open Charts CRNX vs QUREBanner chart's image
Crinetics Pharmaceuticals
Price$29.96
Change-$0.03 (-0.10%)
Volume$1.64M
Capitalization2.81B
uniQure
Price$13.86
Change-$0.37 (-2.60%)
Volume$836.8K
Capitalization759.91M
CRNX vs QURE Comparison Chart in %
Loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QURE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRNX vs. QURE commentary
Jun 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a StrongBuy and QURE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 28, 2025
Stock price -- (CRNX: $30.04 vs. QURE: $13.88)
Brand notoriety: CRNX and QURE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 213% vs. QURE: 52%
Market capitalization -- CRNX: $2.81B vs. QURE: $759.91M
CRNX [@Biotechnology] is valued at $2.81B. QURE’s [@Biotechnology] market capitalization is $759.91M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileQURE’s FA Score has 0 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • QURE’s FA Score: 0 green, 5 red.
According to our system of comparison, QURE is a better buy in the long-term than CRNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 3 TA indicator(s) are bullish while QURE’s TA Score has 3 bullish TA indicator(s).

  • CRNX’s TA Score: 3 bullish, 6 bearish.
  • QURE’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, both CRNX and QURE are a bad buy in the short-term.

Price Growth

CRNX (@Biotechnology) experienced а -1.51% price change this week, while QURE (@Biotechnology) price change was -2.32% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was +31.37%, and the average quarterly price growth was +12.88%.

Reported Earning Dates

CRNX is expected to report earnings on Aug 08, 2025.

QURE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($2.81B) has a higher market cap than QURE($760M). QURE YTD gains are higher at: -21.404 vs. CRNX (-41.248). QURE has higher annual earnings (EBITDA): -138.01M vs. CRNX (-373.49M). CRNX has more cash in the bank: 1.27B vs. QURE (409M). CRNX has less debt than QURE: CRNX (50.8M) vs QURE (66.2M). QURE has higher revenues than CRNX: QURE (20.2M) vs CRNX (760K).
CRNXQURECRNX / QURE
Capitalization2.81B760M370%
EBITDA-373.49M-138.01M271%
Gain YTD-41.248-21.404193%
P/E RatioN/AN/A-
Revenue760K20.2M4%
Total Cash1.27B409M311%
Total Debt50.8M66.2M77%
FUNDAMENTALS RATINGS
CRNX vs QURE: Fundamental Ratings
CRNX
QURE
OUTLOOK RATING
1..100
6253
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
79
Overvalued
PROFIT vs RISK RATING
1..100
67100
SMR RATING
1..100
94100
PRICE GROWTH RATING
1..100
6439
P/E GROWTH RATING
1..100
10092
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

QURE's Valuation (79) in the Biotechnology industry is in the same range as CRNX (92) in the Pharmaceuticals Major industry. This means that QURE’s stock grew similarly to CRNX’s over the last 12 months.

CRNX's Profit vs Risk Rating (67) in the Pharmaceuticals Major industry is somewhat better than the same rating for QURE (100) in the Biotechnology industry. This means that CRNX’s stock grew somewhat faster than QURE’s over the last 12 months.

CRNX's SMR Rating (94) in the Pharmaceuticals Major industry is in the same range as QURE (100) in the Biotechnology industry. This means that CRNX’s stock grew similarly to QURE’s over the last 12 months.

QURE's Price Growth Rating (39) in the Biotechnology industry is in the same range as CRNX (64) in the Pharmaceuticals Major industry. This means that QURE’s stock grew similarly to CRNX’s over the last 12 months.

QURE's P/E Growth Rating (92) in the Biotechnology industry is in the same range as CRNX (100) in the Pharmaceuticals Major industry. This means that QURE’s stock grew similarly to CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXQURE
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
87%
MACD
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 22 days ago
76%
Bullish Trend 3 days ago
74%
Declines
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 1 day ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 1 day ago
85%
Aroon
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QURE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CLBCX36.500.10
+0.27%
American Funds American Balanced 529C
AAAPX12.32N/A
N/A
DWS RREEF Real Assets C
HEOSX17.29N/A
N/A
Hartford Climate Opportunities R4
SGIDX36.09N/A
N/A
Steward Global Equity Income Fund A
NIQCX14.71N/A
N/A
Neuberger Berman International Eq C

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with XNCR. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
-1.22%
XNCR - CRNX
58%
Loosely correlated
-3.10%
TRDA - CRNX
57%
Loosely correlated
-1.57%
IDYA - CRNX
56%
Loosely correlated
-4.04%
RVMD - CRNX
55%
Loosely correlated
-1.49%
DYN - CRNX
55%
Loosely correlated
-4.98%
More

QURE and

Correlation & Price change

A.I.dvisor indicates that over the last year, QURE has been loosely correlated with NAMS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if QURE jumps, then NAMS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QURE
1D Price
Change %
QURE100%
-2.46%
NAMS - QURE
50%
Loosely correlated
+0.65%
HOOK - QURE
44%
Loosely correlated
-0.40%
AXON - QURE
42%
Loosely correlated
+1.82%
ABSI - QURE
40%
Loosely correlated
-3.51%
CRNX - QURE
39%
Loosely correlated
-1.22%
More